Examkin

Question

Difficulty: Very hardInfectious Diseases

An 81-year-old female resident of a skilled nursing facility is currently recovering in the intensive care unit after presenting three days prior with severe distributive shock secondary to a catheter-associated urinary tract infection. On admission, she was hypotensive and tachycardic, and empiric antimicrobial therapy was initiated with intravenous vancomycin and piperacillin-tazobactam. Today, she is hemodynamically stable, off vasopressor support, and her temperature has normalized to 37.1°C (98.8°F). The indwelling urinary catheter was removed on the first day. Both the admission urine and blood cultures have grown *Escherichia coli*. The susceptibility report for the bloodstream isolate is provided below:

Antimicrobial AgentSusceptibility
AmpicillinResistant
CeftriaxoneResistant
CefepimeResistant
Piperacillin-tazobactamSusceptible
GentamicinSusceptible
MeropenemSusceptible

Based on the culture results and the patient's current clinical status, which of the following is the most appropriate definitive pharmacotherapy?

  1. A
    Monotherapy with intravenous piperacillin-tazobactam
  2. B
    Monotherapy with oral fosfomycin
  3. Monotherapy with intravenous meropenemAnswer
  4. D
    Monotherapy with intravenous gentamicin
  5. E
    Combination therapy with intravenous piperacillin-tazobactam and gentamicin

Answer

Monotherapy with intravenous meropenem
The patient has an Escherichia coli bloodstream infection with a classic resistance pattern for an Extended-Spectrum Beta-Lactamase (ESBL) producer, evidenced by resistance to ampicillin and advanced-generation cephalosporins (ceftriaxone, cefepime). For ESBL bacteremia, carbapenems (such as meropenem, imipenem, or ertapenem) are the definitive drug of choice. Although piperacillin-tazobactam frequently tests as susceptible in vitro (due to the tazobactam component inhibiting the ESBL enzyme), robust randomized controlled data (such as the MERINO trial) have clearly demonstrated that definitive therapy with piperacillin-tazobactam results in significantly higher 30-day mortality and clinical failure compared to carbapenems in bloodstream infections. Therefore, despite the patient's initial clinical improvement on empiric therapy, the regimen must be escalated to a carbapenem to ensure definitive cure.

Step-by-Step Solution

1
Analyze the antimicrobial susceptibility report.
Identify resistance to 3rd-generation cephalosporins (ceftriaxone) but susceptibility to carbapenems, indicative of an Extended-Spectrum Beta-Lactamase (ESBL) producing E. coli.
Correct identification of the specific resistance mechanism is mandatory to evaluate true in vivo efficacy versus in vitro testing artifacts.
2
Assess the anatomical site and severity of the infection.
The patient has a confirmed bloodstream infection (bacteremia) originating from the urinary tract.
The efficacy of certain antibiotics varies drastically based on whether the infection is localized (e.g., cystitis) or systemic (e.g., bacteremia).
3
Select the definitive antimicrobial agent.
Transition from empiric piperacillin-tazobactam to a targeted carbapenem (meropenem).
Current IDSA guidelines mandate carbapenems for ESBL bacteremia due to established superiority in mortality outcomes over piperacillin-tazobactam.

Key Concept

Carbapenems are the definitive treatment of choice for bloodstream infections caused by ESBL-producing organisms; piperacillin-tazobactam should be avoided in bacteremia even if reported as susceptible in vitro.
Rate this question

Topics

Infectious Diseases

More questions from this topic